{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:54:43Z","timestamp":1788472483955,"version":"build-2803163510"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Vancomycin is a critical antibiotic used in important infections, and therapeutic drug monitoring (TDM) is recommended. Bayesian forecasting is demonstrated to provide an approach that can improve trough concentration monitoring for dose adjustment. The objective of this study was to determine whether TDM coupled with a Bayesian approach could increase trough concentration target attainment and prevent vancomycin-associated nephrotoxicity in patients with renal insufficiency.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A prospective study was performed using propensity score matching to provide covariate balance in renal insufficiency patients with gram-positive bacterial infections treated with vancomycin. Patients were divided into non-TDM (84 cases) and TDM (84 cases) groups, and their clinical outcomes were compared. The primary endpoints were probability of trough concentration target attainment and incidence of vancomycin-associated nephrotoxicity. A decision-tree model was developed to assess the cost effectiveness of TDM to prevent vancomycin-associated nephrotoxicity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Of the 168 eligible patients, 69 from each group (non-TDM and TDM) were matched based on propensity scores. In the matched cohort, trough concentration target attainment was higher with TDM (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.003). Furthermore, reaching toxic trough concentrations was avoided (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.027) in the TDM group. Multivariate logistic regression analysis confirmed that TDM practice independently reduced the incidence of vancomycin-associated nephrotoxicity in renal insufficiency patients (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.021). According to this reduced nephrotoxicity, the incremental cost-effectiveness ratios of \u00a522,638 per nephrotoxic episode prevented was found for vancomycin TDM.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>TDM coupled with Bayesian forecasting led to an increase in trough concentration target attainment and a decrease in the incidence of vancomycin-associated nephrotoxicity in renal insufficiency patients. In this high-risk population, TDM was demonstrated to be a cost-effective procedure.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000750","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T21:15:35Z","timestamp":1582665335000},"page":"600-609","source":"Crossref","is-referenced-by-count":37,"title":["Therapeutic Drug Monitoring Coupled With Bayesian Forecasting Could Prevent Vancomycin-Associated Nephrotoxicity in Renal Insufficiency Patients: A Prospective Study and Pharmacoeconomic Analysis"],"prefix":"10.1097","volume":"42","author":[{"given":"Ying","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taotao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haisheng","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl 1","key":"R1-20230814","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1086\/491709","article-title":"Vancomycin: a history","volume":"42","author":"Levine","year":"2006","journal-title":"Clin Infect Dis."},{"issue":"suppl 1","key":"R2-20230814","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/491708","article-title":"Vancomycin: a 50-year reassessment","volume":"42","author":"Moellering","year":"2006","journal-title":"Clin Infect Dis."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin Infect Dis."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10156-013-0599-4","article-title":"Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"19","author":"Matsumoto","year":"2013","journal-title":"J Infect Chemother."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Health-Syst Pharm."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1093\/jac\/dkw254","article-title":"Therapeutic drug monitoring of vancomycin: a guideline of the division of therapeutic drug monitoring, Chinese Pharmacological Society","volume":"71","author":"Ye","year":"2016","journal-title":"J Antimicrob Chemother."},{"key":"R7-20230814","first-page":"103","article-title":"Vancomycin toxicity. What is the evidence for dose dependency?","volume":"13","author":"Duffull","year":"1994","journal-title":"Adverse Drug React Toxicol Rev."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-199528040-00005","article-title":"Pharmacokinetic optimisation of vancomycin therapy","volume":"28","author":"Leader","year":"1995","journal-title":"Clin Pharmacokinet."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2165\/00003088-199427030-00001","article-title":"Therapeutic drug monitoring and patient outcome. A review of the issues","volume":"27","author":"Tonkin","year":"1994","journal-title":"Clin Pharmacokinet."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1128\/AAC.03147-14","article-title":"Optimizing the clinical use of vancomycin","volume":"60","author":"\u00c1lvarez","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cmi.2015.04.003","article-title":"Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis","volume":"21","author":"Steinmetz","year":"2015","journal-title":"Clin Microbiol Infect."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(12)60033-6","article-title":"Prevalence of chronic kidney disease in China: a cross-sectional survey","volume":"379","author":"Zhang","year":"2012","journal-title":"Lancet."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/imj.12036","article-title":"Vancomycin therapeutics and monitoring: a contemporary approach","volume":"43","author":"Avent","year":"2013","journal-title":"Intern Med J."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/cid\/ciu398","article-title":"Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?","volume":"59","author":"Lodise","year":"2014","journal-title":"Clin Infect Dis."},{"key":"R15-20230814","first-page":"104","article-title":"Development of decision system for individualization of vancomycin dosage","volume":"53","author":"Gao","year":"2018","journal-title":"Acta Pharm Sin."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med."},{"issue":"suppl_2","key":"R17-20230814","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1093\/cid\/ciy680","article-title":"A prospective multicenter clinical observational study on vancomycin efficiency and safety with therapeutic drug monitoring","volume":"67","author":"Liang","year":"2018","journal-title":"Clin Infect Dis."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/cc2872","article-title":"Acute Dialysis Quality Initiative workgroup. Acute renal failure\u2014definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group","volume":"8","author":"Bellomo","year":"2004","journal-title":"Crit Care."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"e02042","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000343162","article-title":"Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant staphylococcus aureus pneumonia","volume":"58","author":"Suzuki","year":"2012","journal-title":"Chemotherapy."},{"key":"R21-20230814","first-page":"295","article-title":"Clinical application of drug monitoring of vancomycin","volume":"11","author":"Huang","year":"2011","journal-title":"Chin J Infec Chemother."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1177\/106002809402801201","article-title":"Impact of vancomycin therapeutic drug monitoring on patient care","volume":"28","author":"Welty","year":"1994","journal-title":"Ann Pharmacother."},{"key":"R24-20230814","first-page":"1528","article-title":"Population pharmacokinetics of vancomycin and prediction of pharmacodynamics in the Chinese people","volume":"49","author":"He","year":"2014","journal-title":"Acta Pharm Sin."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00228-015-1952-6","article-title":"Population pharmacokinetics of vancomycin in adult Chinese patients with post-craniotomy meningitis and its application in individualised dosage regimens","volume":"72","author":"Lin","year":"2016","journal-title":"Eur J Clin Pharmacol."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"509","DOI":"10.5414\/CP202835","article-title":"Population pharmacokinetics of vancomycin in Chinese pediatric patients","volume":"55","author":"Liu","year":"2017","journal-title":"Int J Clin Pharmacol Ther."},{"key":"R27-20230814","first-page":"1434","article-title":"Population pharmacokinetics of vancomycin in Chinese neonates","volume":"52","author":"Li","year":"2017","journal-title":"Chin Pharm J."},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1214\/09-STS313","article-title":"Matching methods for causal inference: a review and a look forward","volume":"25","author":"Stuart","year":"2010","journal-title":"Stat Sci."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/510393","article-title":"Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship","volume":"44","author":"Dellit","year":"2007","journal-title":"Clin Infect Dis."},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/00007691-199310000-00005","article-title":"Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control","volume":"15","author":"Jelliffe","year":"1993","journal-title":"Ther Drug Monit."},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"1286.e1","DOI":"10.1016\/j.cmi.2019.02.029","article-title":"Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting","volume":"25","author":"Broeker","year":"2019","journal-title":"Clin Microbiol Infect."},{"key":"R32-20230814","first-page":"434","article-title":"Bayesian clinical decision support-guided versus clinician-guided vancomycin dosing in attainment of targeted pharmacokinetic parameters in a paediatric population","volume":"75","author":"Hughes","year":"2020","journal-title":"J Antimicrob Chemother."},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/cir124","article-title":"Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets","volume":"52","author":"Kullar","year":"2011","journal-title":"Clin Infect Dis."},{"key":"R34-20230814","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1345\/aph.1R158","article-title":"The relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran's population: a retrospective analysis","volume":"46","author":"Horey","year":"2012","journal-title":"Ann Pharmacother."},{"key":"R35-20230814","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Palmer LB6 management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis."},{"key":"R36-20230814","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1309\/AJCPDSYS0DVLKFOH","article-title":"What proportion of vancomycin trough levels are drawn too early?: frequency and impact on clinical actions","volume":"137","author":"Morrison","year":"2012","journal-title":"Am J Clin Pathol."},{"key":"R37-20230814","first-page":"21","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"31","author":"Martin","year":"2010","journal-title":"Clin Biochem Rev."},{"key":"R38-20230814","doi-asserted-by":"crossref","first-page":"e01293","DOI":"10.1128\/AAC.01293-17","article-title":"A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity","volume":"61","author":"Finch","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"R39-20230814","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jcpt.12399","article-title":"Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia","volume":"41","author":"Fukumori","year":"2016","journal-title":"J Clin Phar Ther."},{"key":"R40-20230814","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1592\/phco.23.5.643.32199","article-title":"Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity","volume":"23","author":"Darko","year":"2003","journal-title":"Pharmacotherapy."},{"key":"R41-20230814","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0009-9236(96)90060-0","article-title":"Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies","volume":"60","author":"Fern\u00e1ndez de Gatta","year":"1996","journal-title":"Clin Pharmacol Ther."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000750","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:25:15Z","timestamp":1692051915000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000750","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}